Matinas BioPharma Files 8-K: Material Agreement & Equity Sales
Ticker: MTNB · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 8-K |
| Filed Date | Aug 18, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $17.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
Matinas BioPharma inked a material deal and sold equity on 8/15.
AI Summary
Matinas BioPharma Holdings, Inc. filed an 8-K on August 18, 2025, reporting on events that occurred on August 15, 2025. The filing indicates the entry into a material definitive agreement and unregistered sales of equity securities. It also includes financial statements and exhibits.
Why It Matters
This filing signals significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing mentions unregistered sales of equity securities, which can sometimes indicate a need for capital or dilution concerns for existing shareholders.
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Registrant
- August 15, 2025 (date) — Date of earliest event reported
- August 18, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 001-38022 (identifier) — Commission File Number
FAQ
What type of material definitive agreement did Matinas BioPharma enter into?
The filing does not specify the nature of the material definitive agreement, only that one was entered into on August 15, 2025.
What were the details of the unregistered sales of equity securities?
The filing indicates unregistered sales of equity securities occurred on August 15, 2025, but does not provide specific details on the amount or terms.
When was this 8-K report filed?
This 8-K report was filed on August 18, 2025.
What is Matinas BioPharma's principal executive office address?
The principal executive offices are located at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921.
What is the company's standard industrial classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Filing Stats: 637 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2025-08-18 06:30:39
Key Financial Figures
- $0.0001 — s the Company's common stock, par value $0.0001 per share (the "Common Stock") having a
- $17.50 — ck") having a current exercise price of $17.50. The Warrants were issued on April 5, 2
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex10-1.htm (EX-10.1) — 61KB
- 0001641172-25-024520.txt ( ) — 278KB
- mtnb-20250815.xsd (EX-101.SCH) — 3KB
- mtnb-20250815_lab.xml (EX-101.LAB) — 34KB
- mtnb-20250815_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MATINAS BIOPHARMA HOLDINGS, INC. Dated: August 18, 2025 By: /s/ Jerome D. Jabbour Name: Jerome D. Jabbour Title: Chief Executive Officer